全國(guó)服務(wù)熱線：020-8555-7146
程序性死亡1抗體/PD-1 Antibody |
|
|
產(chǎn)品名稱 ： 程序性死亡1抗體/PD-1 Antibody
產(chǎn)品類別 ： IVD診斷抗體原料
品 牌 ： GenomeMe
貨 號(hào) ： IHC001
規(guī) 格 ： 0.1ml/1ml
|
|
詳細(xì)信息 |
|
|
純化方式 ：
緩 沖 液 ：
應(yīng)用說(shuō)明 ：
形 態(tài) ：
產(chǎn)品說(shuō)明 ：
背景描述Description：
程序性死亡1(ProgrammedDeath 1，PD-1)是CD28/CTLA-4家族的一員，表達(dá)于活化的T細(xì)胞、B細(xì)胞和巨噬細(xì)胞表面。新的研究表明PD-1/PD-L1信號(hào)通路可能與抗腫瘤免疫有關(guān)，因?yàn)镻D-L1可誘導(dǎo)活化的T細(xì)胞凋亡或抑制細(xì)胞毒性T細(xì)胞的活性。與CD10和Bcl-6相比，PD-1由較少的B細(xì)胞表達(dá)，因此被認(rèn)為是診斷血管免疫母細(xì)胞性T細(xì)胞淋巴瘤的更特異、更有用的標(biāo)記物。針對(duì)PD-1受體的治療已經(jīng)在包括非小細(xì)胞肺癌、黑色素瘤和腎細(xì)胞癌在內(nèi)的各種癌癥患者中顯示出顯著的臨床療效。
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non–small-cell lung cancer, melanoma, and renal-cell cancer.
Specifications：
Clone IHC001
Source Mouse Monoclonal
Positive Control Tonsil, Lymph Node
Dilution Range 1:50-1:200
參考文獻(xiàn)References：
Dorfman DM, et al. Am J Surg Pathol. 2006; 30:802-10.
Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360-5.
Kobayashi M, et al. J Rheumatol. 2005; 32:2156-63.
Konishi J, et al. Clin Cancer Res. 2004; 10:5094-100.
Mataki N, et al. Am J Gastroenterol. 2007; 102:302-12.
Kim JW, et al. Oncology (Williston Park). 2014; 28:15-28.
Tumeh PC, et al. Nature. 2014; 515:568-71.
D’Incecco A, et al. Br J Cancer. 2015; 112:95-102.
Tykodi SS. Onco Targets Ther. 2014; 7:1349-59.
|
|
| {返回} | |
| |||||||||||
